CaeTrader CaeTrader
Merck MRK Pharma
31.2 Score +2.0 (24h) -2.8 (7d)
Updated 0m ago
Price History
Candle
RSI (14)
MACD (12, 26, 9)
ADX (14)

Score Guide

0 Bearish 50 Neutral 100 Bullish
0 Bullish3 Bearish4 Neutral

Analyst Ratings

66%
29 analysts
Buy
66%
Hold
34%
Sell
0%
Consensus: Buy → stable

Key Financials

Price $113.44
Mkt Cap $280.20B
P/E 31.9
Beta 0.2
EPS $3.56
Div Yield 3.03%
Low $100 Mean $130 High $150
Current: $113.44
Latest News
Barrons.com · 2h ago 0.01
How Hantavirus Made Moderna a Must-Own Stock Again
The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.
GuruFocus.com · 2h ago -0.53
Merck Faces Gardasil Trial After $8.9 Billion Sales Peak
Merck heads toward a July 27 Gardasil trial while defending the HPV vaccine's safety record.
Motley Fool · 3h ago +0.76
2 Dividend Stocks to Double Up On Right Now
They can weather many storms.
Moby · 8h ago -0.09
Codexis, Inc. Q1 2026 Earnings Call Summary
Moby summary of Codexis, Inc.'s Q1 2026 earnings call
24/7 Wall St. · 8h ago -0.01
A $1.5 Million Portfolio That Quietly Pays You $83,400 a Year, No Job Required
An $83,400 annual paycheck sits comfortably above the U.S. median household income of roughly $80,610. Replacing that income with a portfolio, no employer required, is the question this article answers. The basic formula is income target divided by yield equals capital required. The more important issue is what changes across three yield tiers, and why ... A $1.5 Million Portfolio That Quietly Pays You $83,400 a Year, No Job Required
Simply Wall St. · 9h ago -0.95
3 Stocks That Could Be Trading Up To 46.1% Below Their Estimated Intrinsic Value
Over the last 7 days, the United States market has risen 3.2%, contributing to a 31% increase over the past year, with earnings expected to grow by 16% per annum in the coming years. In this thriving environment, identifying stocks that are trading below their estimated intrinsic value can be an effective strategy for investors looking to capitalize on potential growth opportunities.
Healthcare Dive · 9h ago 0.08
Federation of American Hospitals taps new government relations head
Elizabeth Schwartz will head up government relations at the for-profit hospital trade association as health systems brace for federal funding cuts.
MarketBeat · 23h ago -0.03
Codexis Q1 Earnings Call Highlights
Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million
24/7 Wall St. · 23h ago +0.90
Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain
Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both entered 2026 with fresh distributions and updated holdings. The two funds chase dividends through very different rule sets, and the gap between them is wider than the surface suggests. Quality Screen vs. Yield ... Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain
Motley Fool · 1d ago 0.11
Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?
Mounjaro generated $8.66 billion in sales in the first quarter.